

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 07 2001

TECH CENTER 1600/2900

In re application of:

Subramaniam, et al.

Appln. No.: 09/688,069

Filed: October 14, 2000

For: Nucleic Acid Sequences to Proteins
Involved in Tocopherol Synthesis



Art Unit: 1653

Examiner: Not yet assigned

Atty. Docket: 16515.054

**Response to Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures**

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 6, 2001,
Applicants submit the following documents for appropriate action by the U.S. Patent and
Trademark Office:

1. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Substitute sequence listing in computer readable form (CRF) for the above referenced application, on a floppy disk;
3. A Statement Regarding Sequence Submission;
4. A substitute paper copy of the sequence listing (in duplicate); and
5. A Preliminary Amendment to enter the sequence listing into the specification.

Applicants are submitting a substitute computer readable copy of the sequence listing (on a floppy disk), a substitute paper copy of the sequence listing in duplicate and a statement under 37 C.F.R. § 1.821(f) § 1.821(g) in response to the Notice.

It is not believed that any fees are required at this time. However, if extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 50-1824. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1824 referencing matter number 16515.054.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)

June E. Cohan (Reg. No. 43,741)

Date: August 3, 01

ARNOLD & PORTER
555 12th Street, N.W.
Washington, D.C. 20004
202.942.5000 telephone
202.942.5999 facsimile



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov


APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/688,069	10/14/2000	Sai S. Subramaniam	MOCO.008.00US

Barbara Rae-Venter
Rae-Venter Law Group, P.C.
P. O. Box 60039
Palo Alto, CA 94306-0039

Docketed 8/16/01
Due Date 8/16/01
Initial llc

CONFIRMATION NO. 8450

FORMALITIES LETTER



OC00000006154281

Date Mailed: 06/06/2001



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

[Handwritten signature]

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE